雜志介紹

Hormones & Cancer雜志介紹

《Hormones & Cancer》是一本以English為主的未開(kāi)放獲取國(guó)際優(yōu)秀期刊，中文名稱荷爾蒙與癌癥，本刊主要出版、報(bào)道醫(yī)學(xué)-ENDOCRINOLOGY & METABOLISM領(lǐng)域的研究動(dòng)態(tài)以及在該領(lǐng)域取得的各方面的經(jīng)驗(yàn)和科研成果，介紹該領(lǐng)域有關(guān)本專業(yè)的最新進(jìn)展，探討行業(yè)發(fā)展的思路和方法，以促進(jìn)學(xué)術(shù)信息交流，提高行業(yè)發(fā)展。該刊已被國(guó)際權(quán)威數(shù)據(jù)庫(kù)SCIE收錄，為該領(lǐng)域相關(guān)學(xué)科的發(fā)展起到了良好的推動(dòng)作用，也得到了本專業(yè)人員的廣泛認(rèn)可。最新CiteScore 指數(shù)為4.6。

本刊近期中國(guó)學(xué)者發(fā)表的論文主要有：

• WDR76 regulates 5-fluorouracil sensitivity in colon cancer via HRAS

  Author: Hu, Yunlong; Tan, Xiao; Zhang, Lin; Zhu, Xiang; Wang, Xiangyao

• OncoVee (TM)-MiniPDX-guided anticancer treatment for HER2-negative intermediate-advanced gastric cancer patients: a single-arm, open-label phase I clinical study

  Author: Zhang, Baonan; Li, Yuzhen; Zhu, Xiaodan; Chen, Zhe; Huang, Xiaona; Gong, Tingjie; Zheng, Weiwang; Bi, Zhenle; Zhu, Chenyang; Qian, Jingyi; Li, Xiaoqiang; Jin, Chunhui

• Evaluation of predictive and prognostic value of androgen receptor expression in breast cancer subtypes treated with neoadjuvant chemotherapy

  Author: Shi, Zhendong; Liu, Yingxue; Zhang, Shichao; Cai, Shuanglong; Liu, Xu; Meng, Jie; Zhang, Jin

• Inhibition of secretory leukocyte protease inhibitor (SLPI) promotes the PUMA-mediated apoptosis and chemosensitivity to cisplatin in colorectal cancer cells

  Author: Wei, Zhijiang; Liu, Guiying; Jia, Rufu; Zhang, Wei; Li, Li; Zhang, Yuanyuan; Wang, Zhijing; Bai, Xiyong

英文介紹

Hormones & Cancer雜志英文介紹

Hormones and Cancer is a unique multidisciplinary translational journal featuring basic science, pre-clinical, epidemiological, and clinical research papers. It covers all aspects of the interface of Endocrinology and Oncology. Thus, the journal covers two main areas of research: Endocrine tumors (benign & malignant tumors of hormone secreting endocrine organs) and the effects of hormones on any type of tumor. We welcome all types of studies related to these fields, but our particular attention is on translational aspects of research. In addition to basic, pre-clinical, and epidemiological studies, we encourage submission of clinical studies including those that comprise small series of tumors in rare endocrine neoplasias and/or negative or confirmatory results provided that they significantly enhance our understanding of endocrine aspects of oncology. The journal does not publish case studies.